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Genome Editing
Who owns gene editing?

Patents in the time of CRISPR
Jacob S. Sherkow
(Innovation Center for Law
and Technology and New
York Law School, USA)

New gene-editing technologies, like CRISPR, promise revolutionary advances in biology and medicine.
However, several patent disputes in the USA and UK may have complicated who can use CRISPR. What
does this mean for the future of gene editing?
Precisely editing the genetic code of living organisms
has long been a supreme ambition of biologists.
Editing the genome has the potential to cure genetic
diseases, revive extinct species and combat public
health crises, among other advances. The potential
for the technology seems limited only by the human
imagination. Previous efforts in the area, however,
have proven less than satisfactory .
A recent advance in one gene-editing technology,
Clustered Regularly Interspaced Short Palindromic
Repeats—better known as CRISPR—may bring
biologists’ ambitions to fruition. This precisionediting system has so far lived up to its hype: CRISPR
has been demonstrated to work in virtually every cell
type attempted and appears almost infinitely flexible
in modification .
But the promise of the technology has generated
a patent dispute among the technologies’ creators:
Jennifer Doudna of the University of California,
Berkeley, and Emmanuelle Charpentier, now at the
Max Planck Institute for Infection Biology in Berlin,
on one side, and Feng Zhang of the Broad Institute,
on the other. Resolving the patent dispute may
ultimately decide who owns the rights to this crucial
piece of biotechnology. This article outlines the law
surrounding patents on biotechnology and explains
the contours and effects of the current CRISPR
patent disputes.
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Patents
Broadly speaking, inventions present an informational
paradox: often, costly and burdensome research is
required to bring them to fruition, but once developed
the invention becomes known to the public. Without
some law restricting the copying of these inventions,
many researchers may not have the incentive to engage
in foundational research in the first instance.
Since at least the fifteenth century, the solution
to this problem has been some form of patents:
government issued rights to inventors—rights that
allow inventors, for a limited period of time, to prevent
others from copying their inventions. To be clear,
patents are not inventors’ rights to use and develop
their own inventions; they are rights only to exclude
others from copying them. Patents, consequently,
are viewed as “limited rights, for a limited time”.
Nonetheless, this limited right can be tremendously
valuable. Many pharmaceutical patents, for example,
are worth billions of dollars.
Not all inventions deserve patent protection.
Precisely because patents can be so valuable—and
because patentees can essentially exclude others from
developing certain areas of technology—patent laws
throughout the world have established certain standards
in an effort to ensure that only significant advances in
science and technology receive patent protection. Today,
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in the USA and UK, patents may be granted only for
inventions that are new, useful and “inventive” or “non
obvious.” In addition, patentees must sufficiently disclose
their inventions to the public—enough to enable others
to make and use the invention. To meet these twin aims,
patents, as documents, contain two parts: a written
description of the invention, known as the specification,
and the claims, short statements identifying the “metes
and bounds” of the invention. The claims, in essence,
define the patented invention.
In this way, the current system of patents ideally
does double-duty in breaking the informational
paradox of inventions. It encourages researchers to
invest in expensive research by holding up the reward
of a patent if they are successful. And it also requires
inventors to disclose the fruits of that research to the
public. Today, for better or worse, patents form an
integral part of the research and development lifecycle
for a host of industries.

The CRISPR patent dispute
Patent law has long faced the problem of
contemporaneous invention: what to do when two
inventors contemporaneously invent the same or
a similar invention and each file competing patent
applications? In much of the world, administrative
efficiency dictates that the patent should be awarded to
the first person to file. But, up until 2013 in the USA,
the USA Patent and Trademark Office (PTO) awarded
the patent to the first inventor . This presented several
problems for the PTO—especially where, because of
quirks of timing at the Patent Office, a later inventor
but earlier filer was awarded the first patent. Through a
restrictive reading of the patent statute, this circumstance
potentially blocked the first inventor’s patent application
from being awarded.
The current CRISPR dispute involves similar
difficulties. Doudna and Charpentier filed an early

patent application covering a limited form of the
CRISPR technology in May 2012. Zhang filed a similar
application seven months later, in December 2012. But
Zhang’s attorneys requested that the PTO “fast-track”
his application: a procedure allowed—for a fee—on
shorter, less contentious applications. Zhang’s attorneys’
strategy worked and, as a result, Zhang was awarded his
first patent in April 2014 and over a dozen more by the
following year. During this time, however, Doudna and
Charpentier’s application suffered numerous technical
difficulties at the PTO. And through much of 2014, it
appeared that Zhang’s issued patents would block their
applications, even though the duo had good claims as
both the first inventors and first filers.
In April 2015, with the CRISPR patent race slipping
away from them, Doudna’s attorneys requested that the
PTO declare an interference proceeding: a trial, within
the PTO, to determine the first inventor of a disputed
technology. After receiving a recommendation from the
patent examiner responsible for Doudna and Charpentier’s
application, the PTO formally instituted an interference
proceeding in January 2016 .
At its core, the interference proceeding is designed
to answer who invented what, first. To do that, a threejudge panel at the PTO will receive evidence concerning
what Doudna, Charpentier and Zhang did in their
laboratories, what they disclosed in their original patent
applications and how an average molecular biologist
would have viewed this information as the technology
progressed through 2012. In addition, the panel
must determine exactly which parts of Doudna and
Charpentier’s application overlap with Zhang’s patents.
To aid them in that determination, the panel drafts a
“count,” a hypothetical patent claim that covers both
sets of technologies. Moving forward, the scientists’
attorneys will file several sets of motions arguing that the
count does or does not cover the technology in dispute,
or that the count needs to be rewritten or broken up
into several pieces to cover the contested inventions. In
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addition, the attorneys will also file motions arguing that
their respective clients were, in fact, the first to invent the
CRISPR technology. The panel’s ruling on these motions
should come in January 2017 if not earlier.
Outside of the USA, however, no analogue to
interference proceedings exists. European patent offices
faced with the contemporaneous invention problem
simply award the patent to the first filer. But there are
other procedures to contest already issued patents at
their respective patent offices. At the European Patent
Office, for example, anyone may file an opposition
to a patent issued within nine months, arguing that
the granted patent fails the novelty, inventive step or
disclosure requirements. This has, in fact, happened
with the CRISPR technology, where, to date, nine
entities—including one company, CRISPR Therapeutics,
founded by Charpentier—have filed oppositions to one
of Zhang’s European patents. Decisions in those cases
are not expected until the end of 2017, at the earliest.
These disputes—both in the USA and elsewhere—
concerning control of the CRISPR technology suggest
that ownership over the CRISPR patents will take years
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to unravel, and will result in a complicated system of
patent rights throughout the world.

The future of CRISPR research
The patent disputes over CRISPR will likely have significant
impact over the future of research in the area. First and
foremost, the disputes may very well affect the funding
of companies currently engaged in CRISPR research. A
recent Bloomberg report by Caroline Chen and Doni
Bloomfield noted that several drug manufacturers have
entered into funding arrangements with various CRISPR
start-ups, some worth hundreds of millions of dollars. The
companies currently developing CRISPR either have a
direct stake in the outcome of the current patent dispute or
could be affected if the ultimate victor decides to enforce its
patents against them. As a consequence, the patent dispute
may shape which companies are allowed to commercially
develop the CRISPR technology.
Second, the patent dispute may also alter which
research institutions continue to study CRISPR as
a gene-editing technology. Well-heeled research
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institutions that cannot come to a license agreement
with the eventual owner of the CRISPR patents may find
themselves on the outside, looking in. This is important
to mention—especially in the USA—because, contrary
to popular belief, there is no “research exemption” for
patent infringement. In Europe, however, such research
exemptions do exist under the national laws of each
country, but may be limited where academic institutions
partner with commercial developers.
Third, the CRISPR patent dispute, no matter
which way it turns, may signal a fundamental shift
in the litigation and enforcement of foundational
biotechnology. Most revolutions in molecular biology—
like recombinant DNA, PCR and RNAi—have been
patented. And almost without exception, those
technologies have been subject to free and easy licenses.
But the CRISPR patent dispute appears to be shaping
up to something different. It may very well signal a
culture shift in academic research institutions from
pure and translational research into profit-maximizing
commercialization. While this is not altogether bad, it’s
likely to conflict with universities’ broader educational
missions to the public. As a result, which aspects of
CRISPR will become subject to research, and by whom,
may turn on those universities’ financial interests in
developing certain CRISPR technologies rather than
their scientific or therapeutic importance.
Taken together, these shifts may complicate the
future of gene editing. It may be difficult, for example,
simply to determine whether one is infringing one of
the variety of patents covering gene-editing technology.
And even if the CRISPR patent disputes produce a clear
winner, it is unclear how the victor will deploy licenses,
to whom and at what price. Furthermore, gene editing,
and CRISPR in particular, is progressing so rapidly that
is unclear whether new developments will be covered
by the current landscape. As one example, the count at
issue in the USA interference proceeding requires the

“hybridization” of a guide RNA and a tracrRNA . But
it’s unclear whether this allows the RNAs to exist in two
separate pieces or if they need to be linked, covalently or
by sequence, somehow.
To both of their credits, Doudna and Zhang have
supported some “open science” protocols by making
CRISPR constructs available through an online
repository called AddGene. In that way, the scientists
are engaging in that most noble of scientific practices:
the sharing of results. But it remains unclear how their
benevolence jibes with their patents and the current
patent dispute. It is likely that the litigation will need to
be resolved first.
Gene editing, and CRISPR in particular, heralds
a foundational advance in molecular biology. Like
previous advances in biotechnology, CRISPR is subject
to several patents and is at the centre of a current wideranging patent dispute. But the current patent dispute
surrounding CRISPR seems quite different from past
cases. Even with a clear winner, the CRISPR patent
dispute may ultimately complicate who can practise
the technology going forward. It seems, then, that the
development of CRISPR as a technology is a study as
much of law as science.
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